Glioblastoma Multiforme News and Research

RSS

Glioblastoma Multiforme is a fast-growing type of central nervous system tumor that forms from glial (supportive) tissue of the brain and spinal cord and has cells that look very different from normal cells. Glioblastoma multiforme usually occurs in adults and affects the brain more often than the spinal cord. Also called GBM, glioblastoma, and grade IV astrocytoma.

Comprehensive genomic analysis of low-grade brain tumors sorts into three categories

Comprehensive genomic analysis of low-grade brain tumors sorts them into three categories, one of which has the molecular hallmarks and shortened survival of glioblastoma multiforme, the most lethal of brain tumors, researchers reported at the American Association for Cancer Research Annual Meeting 2014.

10 Apr 2014

Multiple genomic data could help improve studies of association between genes and disease

The difference between merely throwing around buzzwords like "personalized medicine" and "big data" and delivering on their medical promise is in the details of developing methods for analyzing and interpreting genomic data. In a pair of new papers, Brown University epidemiologist Yen-Tsung Huang and colleagues show how integrating different kinds of genomic data could improve studies of the association between genes and disease.

10 Apr 2014

Researchers find new molecular targets for aggressive brain tumor

Researchers from the Geisel School of Medicine at Dartmouth will present a scientific poster on Tuesday, April 8, 2014 at the American Association of Cancer Researchers conference in San Diego, CA. The research identifies a potential characteristic for predicting outcome in a deadly form of brain cancer known as glioblastoma multiforme.

9 Apr 2014

DelMar presents pre-clinical study data that evaluates activity of VAL-083 in drug-resistant NSCLC

DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar") today announced the presentation of new data in a poster entitled, "In vivo efficacy of VAL-083 in the treatment of non-small cell lung cancer." DelMar's data was presented on Sunday, April 6, 2014 during the Novel Cytotoxic Strategies Session at the 105th Annual Meeting of the American Association for Cancer Research (AACR) in San Diego.

8 Apr 2014

GenSpera enrolls first patient in Phase II trial of compound G-202 in patients with glioblastoma multiforme

GenSpera, Inc. (OTCQB:GNSZ) announced that the first patient was enrolled in the Phase II clinical trial of its lead compound, G-202, in patients who have glioblastoma multiforme (GBM), the most prevalent type of primary brain cancer.

18 Mar 2014

Agenus reports net loss attributable to common stockholders of $5.8 million for Q4 2013

Agenus Inc., a biopharmaceutical company developing a portfolio of immuno-oncology candidates, including checkpoint modulators (CPMs), heat shock protein vaccines and adjuvants, today announced its financial results and business highlights for the fourth quarter and year ended December 31, 2013.

5 Mar 2014

Maximizing imaging techniques to bridge the gap between diagnosis and treatment of cancer

Glioblastoma multiforme is the most common form of brain cancer and patients with this diagnosis have a life expectancy of less than two years. In spite of the fact that its diagnosis is very good, an appropriate treatment remains elusive.

From Bruker BioSpin - NMR, EPR and Imaging 3 Mar 2014

Study identifies promising target for new drugs to treat lethal form of brain cancer

A molecule in cells that shuts down the expression of genes might be a promising target for new drugs designed to treat the most frequent and lethal form of brain cancer, according to a new study by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.

27 Feb 2014

Scientists develop mathematical method for classifying forms of glioblastoma

Scientists at The Wistar Institute have developed a mathematical method for classifying forms of glioblastoma, an aggressive and deadly type of brain cancer, through variations in the way these tumor cells "read" genes. Their system was capable of predicting the subclasses of glioblastoma tumors with 92 percent accuracy. With further testing, this system could enable physicians to accurately predict which forms of therapy would benefit their patients the most.

18 Feb 2014

Researchers use new technique that can partially move tumors from inoperable locations in brain

One factor that makes glioblastoma cancers so difficult to treat is that malignant cells from the tumors spread throughout the brain by following nerve fibers and blood vessels to invade new locations.

17 Feb 2014

TCGA Research Network identify new potential therapeutic targets for major form of bladder cancer

Investigators with The Cancer Genome Atlas (TCGA) Research Network have identified new potential therapeutic targets for a major form of bladder cancer, including important genes and pathways that are disrupted in the disease.

30 Jan 2014

Research shows promise for developing a method of clearly identifying cancerous tissue during surgery

First-of-its-kind research by the Innovation Institute at Henry Ford Hospital shows promise for developing a method of clearly identifying cancerous tissue during surgery on one of the most common and deadliest types of brain tumor.

30 Jan 2014

Clinical trial of experimental vaccine targets cancer stem cells in patients with recurrent brain tumor

An early-phase clinical trial of an experimental vaccine that targets cancer stem cells in patients with recurrent glioblastoma multiforme, the most common and aggressive malignant brain tumor, has been launched by researchers at Cedars-Sinai's Department of Neurosurgery, Johnnie L. Cochran, Jr. Brain Tumor Center and Department of Neurology.

25 Jan 2014

Agenus' Prophage vaccine Phase 2 study hailed in Neuro-Oncology journal

Agenus Inc., a biotechnology company developing novel immune system activating treatments for cancers and infectious diseases, announced that Phase 2 results of Prophage G-200 vaccine in recurrent patients with glioblastoma multiforme were hailed as 'exciting' and a 'very promising therapy' in an editorial published in Neuro-Oncology, the leading journal of the Society of Neuro-Oncology.

21 Jan 2014

New study gives hope for novel glioblastoma multiforme treatment

A new study is giving researchers hope that novel targeted therapies can be developed for glioblastoma multiforme, the most common and most aggressive form of brain cancer, after demonstrating for the first time that a gene known as melanoma differentiation associated gene-9/syntenin (mda-9/syntenin) is a driving force behind the disease's aggressive and invasive nature.

9 Jan 2014

New approach aims to prevent brain cancer recurrence by attacking tumors at the source

Researchers at the Cedars-Sinai Maxine Dunitz Neurosurgical Institute and Department of Neurosurgery identified immune system targets on cancer stem cells - cells from which malignant brain tumors are believed to originate and regenerate - and created an experimental vaccine to attack them.

6 Jan 2014

BBC TV report profiles NW Bio's DCVax-L Phase III trial for GBM brain cancer

Northwest Biotherapeutics, Inc.("NW Bio"), a biotechnology company developing non-toxic DCVax® personalized immune therapies for solid tumor cancers, announced today that the British Broadcasting Company (BBC) TV network has broadcast a report profiling the first European patient in the Company's Phase III clinical trial of DCVax-L for Glioblastoma multiforme brain cancer (GBM), the most common and aggressive form of brain cancer.

31 Dec 2013

Changes to LZTR1 gene predispose people to develop schwannomas

Changes to a gene called LZTR1 predispose people to develop a rare disorder where multiple tumors called schwannomas form near nerve pathways, according to a study published today in the journal Nature Genetics and led by researchers from the University of Alabama at Birmingham.

24 Dec 2013

TGen, Nemucore, and Barrow collaboration aims for new drugs to treat glioblastoma

The Ben & Catherine Ivy Foundation today announced a $3 million grant to the Translational Genomics Research Institute (TGen), Nemucore Medical Innovations Inc., and Barrow Neurological Institute at St. Joseph's Hospital and Medical Center to help fund significant brain tumor research in Arizona.

18 Dec 2013

Neuro-Oncology publishes promising phase 2 results from Agenus’ brain cancer vaccine study

Agenus Inc., a biotechnology company developing novel immune system activating treatments for cancers and infectious diseases, today announced results published from a Phase 2 study demonstrated that more than 90% of the patients treated with Prophage Series G-200 were alive at six months after surgery and 30% were alive at twelve months.

17 Dec 2013